USD 0.03
(6.67%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 12.27 Million USD | -7.48% |
2022 | 13.27 Million USD | -37.78% |
2021 | 21.33 Million USD | 34.63% |
2020 | 15.84 Million USD | -49.99% |
2019 | 31.67 Million USD | 95.07% |
2018 | 16.24 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | 20 Million USD | 3.63% |
2024 Q2 | 22.51 Million USD | 12.52% |
2023 Q3 | 14.83 Million USD | -5.69% |
2023 FY | 12.27 Million USD | -7.48% |
2023 Q4 | 19.3 Million USD | 30.2% |
2023 Q2 | 15.72 Million USD | -1.79% |
2023 Q1 | 16.01 Million USD | 20.63% |
2022 Q3 | 10.9 Million USD | 243.74% |
2022 Q2 | -7.58 Million USD | -122.68% |
2022 Q1 | 33.44 Million USD | 56.8% |
2022 FY | 13.27 Million USD | -37.78% |
2022 Q4 | 13.27 Million USD | 21.73% |
2021 Q2 | 37.8 Million USD | 16.2% |
2021 FY | 21.33 Million USD | 34.63% |
2021 Q1 | 32.53 Million USD | 105.36% |
2021 Q4 | 21.33 Million USD | 260.52% |
2021 Q3 | -13.28 Million USD | -135.15% |
2020 Q2 | 16.73 Million USD | -16.63% |
2020 FY | 15.84 Million USD | -49.99% |
2020 Q1 | 20.07 Million USD | -36.62% |
2020 Q4 | 15.84 Million USD | 191.75% |
2020 Q3 | -17.26 Million USD | -203.16% |
2019 FY | 31.67 Million USD | 95.07% |
2019 Q4 | 31.67 Million USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | 16.24 Million USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Biotricity, Inc. | 23.09 Million USD | 46.827% |
Cell MedX Corp. | 244.05 Thousand USD | -4931.325% |
Dynatronics Corporation | 6.2 Million USD | -97.92% |
Nemaura Medical Inc. | 9.92 Million USD | -23.718% |
PetVivo Holdings, Inc. | 1.27 Million USD | -861.071% |
RetinalGenix Technologies Inc. | 506.53 Thousand USD | -2324.122% |
Sonendo, Inc. | 26.34 Million USD | 53.386% |
Telesis Bio, Inc. | 32.63 Million USD | 62.375% |
Talis Biomedical Corporation | -57.06 Million USD | 121.518% |
Viveve Medical, Inc. | -13.81 Million USD | 188.895% |